Target SSTR 2/3Class Peptide (somatostatin analogue, DOTA chelator)Other names edotreotide, DOTA-[Tyr³]octreotide
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [¹⁷⁷Lu]Lu-edotreotide (ITM-11) Syntheses and QC ↗ | Therapy | — | 8 | Phase 3 | — |
| [⁹⁰Y]Y-DOTATOC Syntheses and QC ↗ | Therapy | 1,508.5 | 1 | Phase 1 | — |
| [⁶⁸Ga]Ga-DOTATOC Syntheses and QC ↗ | Imaging | — | 6 | Phase 3 | DOTATATE / DOTATOC (Netspot, SomaKit TOC…) US EU FR |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| COMPETE · [177Lu]Lu-edotreotide (ITM-11)NCT03049189 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | ITM Solucin GmbH | 14 |
| COMPOSE · [177Lu]Lu-edotreotide (ITM-11)NCT04919226 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | ITM Solucin GmbH | 10 |
| START-NET · [177Lu]Lu-edotreotide (ITM-11)NCT05387603 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | Lund University Hospital | 1 |
| LEVEL · [177Lu]Lu-edotreotide (ITM-11)NCT05918302 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 4 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2024-519505-35-00 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Centre Hospitalier Universitaire De Nantes | 1 |
| DOTABREAST · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06611891 · Breast | Phase 3 | Recruiting | University Hospital, Grenoble | 1 |
| DOBATOC · [177Lu]Lu-edotreotide (ITM-11)NCT04917484 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Tine Gregersen, MD | 1 |
| LUFOR · [177Lu]Lu-edotreotide (ITM-11)NCT06045260 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| PROMENADE · [177Lu]Lu-edotreotide (ITM-11)NCT04997317 · Meningioma | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2023-504458-36-02 · Breast | Phase 2 | Recruiting | Centre Hospitalier Universitaire Grenoble Alpes | 1 |
| KinLET · [177Lu]Lu-edotreotide (ITM-11)NCT06441331 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | ITM Solucin GmbH | 3 |
| [177Lu]Lu-edotreotide (ITM-11)NCT03044977 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | David Bushnell | 1 |
| OPERANDI-NET · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06256705 · Gastroenteropancreatic NETs | No phase | Recruiting | Assistance Publique - Hôpitaux de Paris | 1 |
| GATEDOTA · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06467968 · Inflammatory diseases | No phase | Recruiting | Central Hospital, Nancy, France | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06773624 · Gastroenteropancreatic NETs | No phase | Recruiting | European Institute of Oncology | 1 |
| 2026-07 | COMPETE · positiveVersus everolimus in progressive G1-G2 GEP-NETs, progression-free survival of 23.9 vs 14.1 months (HR 0.67), with half as many grade 3-4 adverse events (18% vs 40%). | Lancet ↗ |
1,186 publications in PubMed for the query below; the most recent:
DOTATOC[tiab] OR edotreotide[tiab] OR "DOTA-TOC"[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
DOTATOC. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/dotatoc/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.